Amylin and the amylin receptors in migraine: Is there another pathway to target?

IF 4.6 2区 医学 Q1 CLINICAL NEUROLOGY
Cephalalgia Pub Date : 2025-05-01 Epub Date: 2025-05-19 DOI:10.1177/03331024251340066
David Moreno-Ajona, Helin Gosalia, Jan Hoffmann, Peter J Goadsby
{"title":"Amylin and the amylin receptors in migraine: Is there another pathway to target?","authors":"David Moreno-Ajona, Helin Gosalia, Jan Hoffmann, Peter J Goadsby","doi":"10.1177/03331024251340066","DOIUrl":null,"url":null,"abstract":"<p><p>Here, we review the available evidence implicating amylin in migraine, its relationship with calcitonin gene-related peptide (CGRP) and its potential utility as a therapeutic target. The pathophysiology of migraine is currently better understood and the role of CGRP is key. Treatments targeting this pathway have been successful and migraine is a complex disorder, with so many molecules being implicated. Amylin, as for CGRP, is part of the calcitonin/CGRP peptide family. Some therapies intended to block the CGRP pathway can also target amylin receptors. Similar to CGRP, amylin can trigger migraine attacks in a provocation study. Amylin plasma levels have been highlighted as a potential migraine biomarker in one study in migraine patients. Moreover, some preclinical studies in rodents have also discussed sex differences. Comprehending the distinct and overlapping mechanisms between amylin and CGRP signalling could develop further our understanding of migraine pathophysiology. In summary, this review reveals, through initial studies, that targeting the amylin pathway may have a potential role as a novel treatment option for those who may not respond to other treatments, or as a better alternative.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 5","pages":"3331024251340066"},"PeriodicalIF":4.6000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cephalalgia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03331024251340066","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Here, we review the available evidence implicating amylin in migraine, its relationship with calcitonin gene-related peptide (CGRP) and its potential utility as a therapeutic target. The pathophysiology of migraine is currently better understood and the role of CGRP is key. Treatments targeting this pathway have been successful and migraine is a complex disorder, with so many molecules being implicated. Amylin, as for CGRP, is part of the calcitonin/CGRP peptide family. Some therapies intended to block the CGRP pathway can also target amylin receptors. Similar to CGRP, amylin can trigger migraine attacks in a provocation study. Amylin plasma levels have been highlighted as a potential migraine biomarker in one study in migraine patients. Moreover, some preclinical studies in rodents have also discussed sex differences. Comprehending the distinct and overlapping mechanisms between amylin and CGRP signalling could develop further our understanding of migraine pathophysiology. In summary, this review reveals, through initial studies, that targeting the amylin pathway may have a potential role as a novel treatment option for those who may not respond to other treatments, or as a better alternative.

偏头痛中的胰淀素和胰淀素受体:是否存在其他途径?
在这里,我们回顾了现有的证据暗示在偏头痛,它与降钙素基因相关肽(CGRP)的关系和它的潜在效用作为一个治疗靶点。目前对偏头痛的病理生理有了更好的了解,CGRP的作用是关键。针对这一途径的治疗已经取得了成功,偏头痛是一种复杂的疾病,涉及到如此多的分子。Amylin,和CGRP一样,是降钙素/CGRP肽家族的一部分。一些旨在阻断CGRP通路的疗法也可以靶向胰淀素受体。与CGRP类似,在一项刺激研究中,胰淀素可以引发偏头痛发作。在一项偏头痛患者的研究中,胰淀素血浆水平被强调为潜在的偏头痛生物标志物。此外,一些啮齿类动物的临床前研究也讨论了性别差异。了解胰淀素和CGRP信号传导之间不同的重叠机制可以进一步加深我们对偏头痛病理生理的理解。综上所述,本综述通过初步研究表明,针对amylin通路可能作为一种新的治疗方案,或作为一种更好的替代方案,对那些可能对其他治疗无效的患者具有潜在的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cephalalgia
Cephalalgia 医学-临床神经学
CiteScore
10.10
自引率
6.10%
发文量
108
审稿时长
4-8 weeks
期刊介绍: Cephalalgia contains original peer reviewed papers on all aspects of headache. The journal provides an international forum for original research papers, review articles and short communications. Published monthly on behalf of the International Headache Society, Cephalalgia''s rapid review averages 5 ½ weeks from author submission to first decision.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信